Myxoma Virus Sensitizes Cancer Cells to Gemcitabine and Is an Effective Oncolytic Virotherapeutic in Models of Disseminated Pancreatic Cancer
Open Access
- 1 April 2012
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy
- Vol. 20 (4), 759-768
- https://doi.org/10.1038/mt.2011.293
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Myxoma Virus: Propagation, Purification, Quantification, and StorageCurrent Protocols in Microbiology, 2010
- Intelligent Design: Combination Therapy With Oncolytic VirusesMolecular Therapy, 2010
- Myxoma Virus Expressing Interleukin-15 Fails To Cause Lethal Myxomatosis in European RabbitsJournal of Virology, 2009
- Pharmacologic and Chemical Adjuvants in Tumor VirotherapyChemical Reviews, 2009
- Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PVClinical Cancer Research, 2009
- Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With CyclophosphamideMolecular Therapy, 2008
- Preclinical Pharmacology and Toxicology of Intravenous MV-NIS, an Oncolytic Measles Virus Administered With or Without CyclophosphamideClinical Pharmacology & Therapeutics, 2007
- M-T5, the Ankyrin Repeat, Host Range Protein of Myxoma Virus, Activates Akt and Can Be Functionally Replaced by Cellular PIKE-AJournal of Virology, 2007
- Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor CellsJournal of Virology, 2007
- Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cellsBritish Journal of Cancer, 2007